Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT00796991
- Phase
- PHASE1
- Status
- Completed
Conditions
- Advanced Melanoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ipilimumab — DRUGSolution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
- Carboplatin — DRUGSolution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
- Paclitaxel — DRUGSolution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
- Dacarbazine — DRUGSolution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Study Details
The purpose of this clinical research study is to learn the pharmacokinetics of Ipilimumab when combined with Paclitaxel/Carboplatin or Dacarbazine
Key Dates
- Start date
- Feb 28, 2009
- Status verified
- Dec 2013
- Primary completion
- Nov 30, 2009
- Completion
- Oct 31, 2012
Study Design
- Enrollment
- 72 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Arm A
- Active Comparator: Arm B
- Active Comparator: Arm C
Primary Outcome Measure
Pharmacokinetic Parameter Maximum Observed Serum Concentration (Cmax) for Ipilimumab, Paclitaxel, Dacarbazine and the Active Metabolite for Dacarbazine, 5-aminoimidazole-4carboxamide (AIC)- Pharmacokinetic Analysis Population [ Time Frame: Day 1 (0 h) to Day 43 ]
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The Angeles Clinic & Research Inst. | Los Angeles | California | 90025 | - |
| H Lee Moffit Cancer Cnt And Res Inst | Tampa | Florida | 33612 | - |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | - |
| Blumenthal Cancer Center, Carolinas Medical Center | Charlotte | North Carolina | 28204 | - |
Find similar trials in Los Angeles, CA
Related Studies
- Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)PHASE3 · Recruiting · Immunocore Ltd · Phoenix, Arizona
- The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint InhibitorsPHASE1 · Recruiting · University of California, Davis · Sacramento, California
- At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced CancerPHASE2 · Recruiting · Mayo Clinic · Jacksonville, Florida
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)PHASE3 · Recruiting · Immunocore Ltd · Tucson, Arizona